Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma.
González-Calle V et al. Haematologica. 2017 Jan 25. pii: haematol.2016.158345. doi: 10.3324/haematol.2016.158345. [Epub ahead of print].

Capillary electrophoresis analysis of N-glycosylation changes of serum paraproteins in multiple myeloma.
Kovacs Z et al. Electrophoresis. 2017 Jan 24. doi: 10.1002/elps.201700006. [Epub ahead of print].

Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics.
Chakraborty R et al. Biol Blood Marrow Transplant. 2017 Jan 20. pii: S1083-8791(17)30201-X. doi: 10.1016/j.bbmt.2017.01.076. [Epub ahead of print].

Early Prognostic Value of Monitoring Serum Free Light Chain in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.
Özkurt ZN et al. Cancer Invest. 2017 Jan 23:1-7. doi: 10.1080/07357907.2016.1270958. [Epub ahead of print].

Next generation flow (NGF) for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.
Flores-Montero J et al. Leukemia. 2017 Jan 20. doi: 10.1038/leu.2017.29. [Epub ahead of print].

Circulating proteasomes: circling myeloma with a new potential biomarker.
Spektor TM et al. Leuk Lymphoma. 2017 Mar;58(3):513-515. doi: 10.1080/10428194.2016.1274981. Epub 2017 Jan 16.

Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.
Grzasko N et al. Leuk Lymphoma. 2017 Jan 16:1-15. doi: 10.1080/10428194.2016.1272684. [Epub ahead of print].

+1q: amplifying the bad genes in myeloma.
Chakraborty R et al. Leuk Lymphoma. 2017 Jan 16:1-6. doi: 10.1080/10428194.2016.1272689. [Epub ahead of print].

Prognostic Implications of Monosomies in Patients With Multiple Myeloma.
Shin SY et al. Clin Lymphoma Myeloma Leuk. 2016 Dec 26. pii: S2152-2650(16)30953-3. doi: 10.1016/j.clml.2016.12.001. [Epub ahead of print].

Upregulated lncRNA-PCAT1 is closely related to clinical diagnosis of multiple myeloma as a predictive biomarker in serum.
Shen X et al. Cancer Biomark. 2017 Jan 3. doi: 10.3233/CBM-160158. [Epub ahead of print].

Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma.
Butrym A et al. Arch Immunol Ther Exp (Warsz). 2017 Jan 12. doi: 10.1007/s00005-016-0442-6. [Epub ahead of print].

p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma.
Hideshima T et al. Blood. 2017 Jan 12. pii: blood-2016-09-738500. doi: 10.1182/blood-2016-09-738500. [Epub ahead of print].

Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation.
Shah GL et al. Leuk Lymphoma. 2017 Jan 12:1-9. doi: 10.1080/10428194.2016.1260126. [Epub ahead of print].

IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma.
Bolomsky A et al. Am J Hematol. 2017 Jan 4. doi: 10.1002/ajh.24634. [Epub ahead of print]

[68Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma – Comparison to [18F]FDG and laboratory values.
Lapa C et al. Theranostics. 2017 Jan 1;7(1):205-212. doi: 10.7150/thno.16576. eCollection 2017.

Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients.
Ghermezi M et al. Haematologica. 2016 Dec 29. pii: haematol.2016.150896. doi: 10.3324/haematol.2016.150896. [Epub ahead of print].

PKM2 and other key regulators of Warburg effect positively correlate with CD147 (EMMPRIN) gene expression and predict survival in multiple myeloma.
Panchabhai S et al. Leukemia. 2017 Jan 13. doi: 10.1038/leu.2016.389. [Epub ahead of print].

IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).
Krönke J et al. Leukemia. 2017 Jan 20. doi: 10.1038/leu.2016.384. [Epub ahead of print].